Gilead Sciences, Inc. (NASDAQ:GILD) is AustralianSuper Pty Ltd's 9th Largest Position

AustralianSuper Pty Ltd grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 168.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,057,707 shares of the biopharmaceutical company's stock after acquiring an additional 1,919,438 shares during the period. Gilead Sciences comprises about 1.9% of AustralianSuper Pty Ltd's investment portfolio, making the stock its 9th biggest position. AustralianSuper Pty Ltd owned about 0.25% of Gilead Sciences worth $342,616,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in GILD. FMR LLC boosted its stake in Gilead Sciences by 21.6% during the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after buying an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP boosted its stake in Gilead Sciences by 3.1% during the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after buying an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC boosted its stake in Gilead Sciences by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after buying an additional 749,047 shares during the last quarter. Norges Bank purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $1,789,254,000. Finally, Northern Trust Corp raised its position in Gilead Sciences by 19.7% during the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after purchasing an additional 2,458,954 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

GILD stock traded down $0.58 during midday trading on Friday, reaching $108.22. The stock had a trading volume of 6,627,889 shares, compared to its average volume of 7,673,118. The stock has a market cap of $134.62 billion, a PE ratio of 22.78, a P/E/G ratio of 0.70 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The firm has a fifty day simple moving average of $108.81 and a two-hundred day simple moving average of $105.26. Gilead Sciences, Inc. has a 52-week low of $70.78 and a 52-week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company's revenue was down .3% on a year-over-year basis. During the same quarter last year, the business posted ($1.32) EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.92%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total value of $277,575.00. Following the sale, the chief financial officer directly owned 162,610 shares in the company, valued at approximately $18,054,588.30. The trade was a 1.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total value of $333,090.00. Following the transaction, the insider owned 117,168 shares in the company, valued at approximately $13,009,163.04. This represents a 2.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 72,000 shares of company stock valued at $7,844,775 over the last quarter. Insiders own 0.27% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on GILD. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Cantor Fitzgerald began coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Oppenheimer decreased their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, Morgan Stanley boosted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $111.38.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.